Table 2.

Prognostic factors for survival. All baseline variables shown in Table 1 were analyzed (univariate, log-rank test). Those with P value <0.1 were carried forward to multivariate Cox regression analysis and are shown here.

Characteristic	Median survival (months)	P  value
		Univariate1	Multivariate
Karnofsky PS
90–100	18.3	0.0001	0.0001
70–80	9.4
≤60	2.1
Known brain metastases
No	9.7	0.008	n.s.
Yes	3.6
Known liver metastases
No	9.7	0.037	0.039
Yes	2.8
Pleural effusion
No	9.4	0.007	0.039
Yes	1.3
Number of metastatic sites
Max. 2	9.7	0.054	n.s.
3 or more	2.8
Progressive disease outside RT target volume
No	12.6	0.033	n.s.
Yes	5.5
Use of opioid analgetics
No	24.5	0.02	n.s.
Yes	5.2
Use of steroids
No	12.2	0.002	0.015
Yes	3.6
Serum albumin
Low	9.7	0.001	n.s.
Normal	2.8
Serum alkaline phosphatase
Normal	15.1	0.027	n.s.
Elevated	4.1
Serum creatinine
Low	1.6	0.0001	n.s.
Normal	9.7
Elevated	15.1
Serum C-reactive protein
Normal	18.3	0.0001	n.s.
Elevated but less than 30 mg/L	12.6
Elevated 30–60 mg/L	5.3
Elevated >60 mg/L	2.6
Thrombocyte count
Low	12.7	0.038	n.s.
Normal	9.7
High	4.0
Number of abnormal blood tests2
Max. 1	12.7
2	5.8	0.008	n.s.
3 or more	3.0
Smoking status
Current smoker	4.3	0.063	n.s.
No	9.7
Time from first cancer diagnosis
Shorter than median (47 months)	5.3	0.089	n.s.
Longer than median	9.7

RT: radiotherapy; PS: performance status.

¹If more than 2 groups, P value from log-rank test pooled over all strata.

²All tests shown in Table 1 were considered.

Significance levels were not corrected for multiple tests.